Abstract
Tumor necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a member of the tumor necrosis factor (TNF) superfamily that induces apoptosis upon binding to its death domain-containing transmembrane receptors. The preferential toxicity of TRAIL to cancer cells and the sparing of normal cells make it an ideal cancer therapeutic agent. TRAIL induces apoptosis via the extrinsic death receptor apoptotic pathway and activates the JNK, ERK, Akt and NF-κB signaling cascades. However, not all cancer cells are sensitive to TRAIL therapy. This may limit its efficacy in the clinic, although ways have already been identified to overcome resistance by combining TRAIL with chemotherapeutic and other biological agents. This review focuses on TRAIL receptor-targeting as anticancer therapy, the apoptotic signaling pathways induced by TRAIL receptors, the prognostic implications of TRAIL receptor expression and modulation by combination therapies. The mechanisms of TRAIL resistance and strategies to overcome drug resistance will also be addressed. Finally, the progress of TRAIL and DR4/DR5-specific agonistic antibodies in clinical trials and the development of new receptor-selective TRAIL variants are discussed including future directions for apoptosis inducing therapy.
Keywords: apoptosis, cancer, DR4, DR5, DcR1, TRAIL, clinical trials, p53, TNF, combination therapy
Current Drug Targets
Title: Targeting Trail Towards the Clinic
Volume: 12 Issue: 14
Author(s): Devalingam Mahalingam, Corina N.A.M. Oldenhuis, Eva Szegezdi, Francis J. Giles, Elisabeth G.E. de Vries, Steven de Jong and Steffan T. Nawrocki
Affiliation:
Keywords: apoptosis, cancer, DR4, DR5, DcR1, TRAIL, clinical trials, p53, TNF, combination therapy
Abstract: Tumor necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a member of the tumor necrosis factor (TNF) superfamily that induces apoptosis upon binding to its death domain-containing transmembrane receptors. The preferential toxicity of TRAIL to cancer cells and the sparing of normal cells make it an ideal cancer therapeutic agent. TRAIL induces apoptosis via the extrinsic death receptor apoptotic pathway and activates the JNK, ERK, Akt and NF-κB signaling cascades. However, not all cancer cells are sensitive to TRAIL therapy. This may limit its efficacy in the clinic, although ways have already been identified to overcome resistance by combining TRAIL with chemotherapeutic and other biological agents. This review focuses on TRAIL receptor-targeting as anticancer therapy, the apoptotic signaling pathways induced by TRAIL receptors, the prognostic implications of TRAIL receptor expression and modulation by combination therapies. The mechanisms of TRAIL resistance and strategies to overcome drug resistance will also be addressed. Finally, the progress of TRAIL and DR4/DR5-specific agonistic antibodies in clinical trials and the development of new receptor-selective TRAIL variants are discussed including future directions for apoptosis inducing therapy.
Export Options
About this article
Cite this article as:
Mahalingam Devalingam, N.A.M. Oldenhuis Corina, Szegezdi Eva, J. Giles Francis, G.E. de Vries Elisabeth, de Jong Steven and T. Nawrocki Steffan, Targeting Trail Towards the Clinic, Current Drug Targets 2011; 12 (14) . https://dx.doi.org/10.2174/138945011798829357
DOI https://dx.doi.org/10.2174/138945011798829357 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetes and Nutritional Screening in Post-Bariatric Patients
Current Diabetes Reviews Myogenic Properties of Brain and Cardiac Vessels and their Relation to Disease
Current Vascular Pharmacology Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets CGRP-Receptor Antagonism in Migraine Treatment
CNS & Neurological Disorders - Drug Targets Evaluation of In Vivo Efficacy of Aqueous Extract of Aerial Parts of Cynodon dactylon in Rats with Simultaneous Type 2 Diabetes and Hypertension
Current Bioactive Compounds Discovery and Advancement of Farnesyl Transferase Inhibitors as Potential Anticancer Therapeutic Agents: SCH 66336 a Case Study
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents 6-Oxo-Morphinane Oximes: Pharmacology, Chemistry and Analytical Application
Current Medicinal Chemistry Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Blood Pressure Control and Diabetic Retinopathy
Current Hypertension Reviews Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Increase in Pharmacological Activity of Drugs in their Clathrates with Plant Glycosides
Letters in Drug Design & Discovery Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety Malaria Stage-Specific Vaccine Candidates
Current Pharmaceutical Design Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis
Current Pharmaceutical Design Neurotoxicity of Insecticides
Current Medicinal Chemistry Syncope: Review of Monitoring Modalities
Current Cardiology Reviews Regulation of Angiogenesis by the Kallikrein-Kinin System
Current Pharmaceutical Design Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor
CNS & Neurological Disorders - Drug Targets